Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
CytoSorbents Corp has a consensus price target of $5.6 based on the ratings of 5 analysts. The high is $10 issued by D. Boral Capital on June 25, 2025. The low is $1 issued by HC Wainwright & Co. on May 15, 2025. The 3 most-recent analyst ratings were released by D. Boral Capital, D. Boral Capital, and HC Wainwright & Co. on June 25, 2025, May 15, 2025, and May 15, 2025, respectively. With an average price target of $7 between D. Boral Capital, D. Boral Capital, and HC Wainwright & Co., there's an implied 469.11% upside for CytoSorbents Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/25/2025 | Buy Now | 713.01% | D. Boral Capital | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
05/15/2025 | Buy Now | 713.01% | D. Boral Capital | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
05/15/2025 | Buy Now | -18.7% | HC Wainwright & Co. | Sean Lee58% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
05/02/2025 | Buy Now | 713.01% | D. Boral Capital | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
04/03/2025 | Buy Now | -18.7% | HC Wainwright & Co. | Sean Lee58% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
04/01/2025 | Buy Now | 713.01% | D. Boral Capital | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
02/25/2025 | Buy Now | 713.01% | D. Boral Capital | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
01/13/2025 | Buy Now | 713.01% | D. Boral Capital | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
01/03/2025 | Buy Now | 713.01% | D. Boral Capital | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
11/12/2024 | Buy Now | 713.01% | D. Boral Capital | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
11/11/2024 | Buy Now | -18.7% | HC Wainwright & Co. | Sean Lee58% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
11/08/2024 | Buy Now | 713.01% | EF Hutton | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
11/04/2024 | Buy Now | 713.01% | EF Hutton | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
10/22/2024 | Buy Now | 713.01% | EF Hutton | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
10/01/2024 | Buy Now | 713.01% | EF Hutton | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
08/14/2024 | Buy Now | 713.01% | EF Hutton | Jason Kolbert51% | $10 → $10 | Maintains | Buy | Get Alert |
08/14/2024 | Buy Now | -18.7% | HC Wainwright & Co. | Sean Lee58% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
07/29/2024 | Buy Now | 713.01% | EF Hutton | Jason Kolbert51% | → $10 | Initiates | → Buy | Get Alert |
05/15/2024 | Buy Now | 143.9% | B. Riley Securities | Yuan Zhi37% | → $3 | Reiterates | Buy → Buy | Get Alert |
05/07/2024 | Buy Now | -18.7% | HC Wainwright & Co. | Sean Lee58% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
03/15/2024 | Buy Now | -18.7% | HC Wainwright & Co. | Sean Lee58% | $1 → $1 | Reiterates | Neutral → Neutral | Get Alert |
12/29/2023 | Buy Now | -18.7% | HC Wainwright & Co. | Sean Lee58% | $5.5 → $1 | Downgrade | Buy → Neutral | Get Alert |
09/07/2023 | Buy Now | 225.2% | B. Riley Securities | Justin Walsh42% | → $4 | Reinstates | Buy → Buy | Get Alert |
08/02/2023 | Buy Now | 347.15% | HC Wainwright & Co. | Sean Lee58% | → $5.5 | Reiterates | Buy → Buy | Get Alert |
05/03/2023 | Buy Now | 347.15% | HC Wainwright & Co. | Sean Lee58% | → $5.5 | Reiterates | → Buy | Get Alert |
03/10/2023 | Buy Now | 347.15% | HC Wainwright & Co. | Sean Lee58% | → $5.5 | Reiterates | → Buy | Get Alert |
11/04/2022 | Buy Now | 347.15% | HC Wainwright & Co. | Sean Lee58% | $9 → $5.5 | Maintains | Buy | Get Alert |
The latest price target for CytoSorbents (NASDAQ:CTSO) was reported by D. Boral Capital on June 25, 2025. The analyst firm set a price target for $10.00 expecting CTSO to rise to within 12 months (a possible 713.01% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for CytoSorbents (NASDAQ:CTSO) was provided by D. Boral Capital, and CytoSorbents maintained their buy rating.
There is no last upgrade for CytoSorbents
The last downgrade for CytoSorbents Corp happened on December 29, 2023 when HC Wainwright & Co. changed their price target from $5.5 to $1 for CytoSorbents Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytoSorbents, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytoSorbents was filed on June 25, 2025 so you should expect the next rating to be made available sometime around June 25, 2026.
While ratings are subjective and will change, the latest CytoSorbents (CTSO) rating was a maintained with a price target of $10.00 to $10.00. The current price CytoSorbents (CTSO) is trading at is $1.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.